- Featured
When your joints ache...everyday life becomes a chore.
Osteoarthritis commonly affects the hips, knees, hands, & spine, causing joint pain and stiffness that can interfere with your daily activities. We are conducting a research study of an investigational medication to treat arthritis pain. Volunteers 50 or older with osteoarthritis symptoms for are needed to join this study. Qualified participants receive study-related doctor’s care & study medication, along with up to $350 compensation. To learn more you may contact us on-line or call 619-660-9068 / 1-800-NEW- STUDY.
Phase
N/ASpan
Sponsor
San Diego, California
Recruiting
- Featured
Does Severe PMS Rule Your Life?
" _My premenstrual symptoms are more severe than other women I know. Once a month, I feel my life spinning out of control, it causes me and everyone around me to suffer._ " If these feelings persist month after month, noticeably affecting your relationships with the people around you and making household or work activities difficult to complete, you may have severe PMS. We are looking for women 18-40, not taking contraceptives, to join in a research study of an investigational medication to treat this disorder. Participants receive study-related medication & physical exam, psychological & laboratory evaluation, and up to $275 compensation To learn more you may contact us on-line or call 619-660-9068 / 1-800-NEW- STUDY.
Phase
N/ASpan
Sponsor
San Diego, California
Recruiting
- Featured
Is your child struggling in School?
Is your child easily distracted? Is it hard for him to pay attention or wait his turn? Is it difficult for him to sit down to work without fidgeting or jumping up to do something else? Does he often act first and think later? Do these behaviors affect how he gets along with family and friends? If this sounds like your child, he or she may be eligible to participate in a national research study of an investigational non-stimulant medication for boys and girls who experience these symptoms. Volunteers 6 to 16 are needed to join this study. Eligible participants receive study-related doctor's care, extensive diagnostic evaluation & study medication, along with compensation for time & travel. To learn more, with no obligation, call: ENCOMPASS CLINICAL RESEARCH at 1-800-NEW-STUDY
Phase
3Span
Sponsor
San Diego, California
Recruiting
- Featured
Do you have breathing problems?
Does COPD, Chronic Bronchitis, or Emphysema affect your breathing? We are looking for volunteers to join a research study of an investigational medication for the treatment of COPD. To be eligible, you must: * be 35 & older * be a current or former smoker (at least 1 pack/day for 15 years) * have no history of asthma and not be on oxygen therapy * be taking a prescription drug for COPD (at least 3 mos.) Participants receive, at no cost: * study-related doctor’s care & medication * up to $550 compensation for time and travel (6 visits over 9 weeks) To learn more you may contact us on-line or call 619-660-9068 / 1-800-NEW- STUDY
Phase
N/ASpan
Sponsor
San Diego, California
Recruiting
- Featured
Do you have heart disease or diabetes? Lowering cholesterol lowers risk of heart attack or stroke.
If you have diabetes or heart disease, reducing health risk factors can improve your quality of life. Lowering blood cholesterol levels that are too high reduces the risk for developing heart disease and lessens the chance of heart attack, stroke or dying of coronary heart disease (CHD). A clinical research study is being conducted to evaluate the effectiveness and safety of an investigational drug that may help to lower cholesterol levels compared with two drugs approved by the Food and Drug Administration for the treatment of high cholesterol. **You may qualify to participate if you are 18 or older and have CHD, diabetes or are at high risk for CHD.** Qualified participants receive study-related doctor’s care, study medication, study- related lab work, & dietary counseling at no cost, along with up to $250 in compensation. To learn more you may contact us on-line or call 619-660-9068 / 1-800-NEW- STUDY.
Phase
N/ASpan
Sponsor
San Diego, California
Recruiting
- Featured
IBS...Irritable Bowel Syndrome
IBS is a common gastrointestinal disorder characterized by a wide range of symptoms such as persistent & recurrent abdominal pain, intestinal spasms, diarrhea, constipation, gas bloating, urgent bowel movements, & a feeling of incomplete emptying. IBS research has led to new treatments for this disorder. Volunteers are needed to join in a research study of an investigational medication for IBS symptoms. To be eligible you must be 18 or older & have either an established IBS diagnosis for at least 6 mos. or a 6 mos. history of symptoms. Participants receive: * study-related care & medication * dietary counseling from our registered dietician * up to $250 compensation To learn more you may contact us on-line or call 619-660-9068 / 1-800-NEW- STUDY.
Phase
N/ASpan
Sponsor
San Diego, California
Recruiting
- Featured
Do you organize your life around chronic migraine pain?
If you are looking for treatment options to manage your migraine pain, we may be able to help. Volunteers are needed to participate in a national research study of an investigational nasal spray medication to treat migraine pain. You may qualify for this study if you are 18 to 65 and suffer from at least 2 migraine attacks a month.. Qualified participants receive study-related care and study-medication along with compensation for time and travel (only 3 office visits required). To learn more you may contact us on-line or call 619-660-9068 / 1-800-NEW- STUDY.
Phase
N/ASpan
Sponsor
San Diego, California
Recruiting
- Featured
Knee Pain?
Do you suffer from osteoarthritis knee pain? Does it interfere with your daily actrivities? Every day research uncovers new information about arthritis therapies. Your involvement in studies could help in the development of new medications that may benefit those struggling with arthritis pain. A global research company is investigating a drug to treat osteoarthritis pain. If you are 40 to 75 and suffer from knee pain, we need you to join a 10 week clinical trial. Volunteers receive study-related medication and care along with up to $600 compensation for time and travel. To learn more you may contact us on-line or call 619-660-9068 / 1-800-NEW- STUDY.
Phase
N/ASpan
Sponsor
San Diego, California
Recruiting
Randomized Controlled Trial Comparing Suture Button Versus Fibulink Fixation for Acute Ankle Syndesmosis Injuries
Ankle fractures are a common injury with potentially significant morbidity. Syndesmosis injury occurs in 10% to 13% of ankle fractures and poses a greater risk to long-term outcomes for patients1,2. If not recognized and adequately reduced, injuries to the syndesmosis have shown to result in instability, persistent pain, and post-traumatic arthritis3. 11% of cases are accompanied by symptomatic advanced osteoarthritis after fixation of the syndesmosis4. The gold standard for syndesmosis fixation has traditionally been screw fixation5. However, issues with screw fixation include screw breakage, screw loosening, reoperation, and malreduction6-8. This has been speculated to be a result of the ankle syndesmosis, a dynamic construct, being inappropriately fixed with static fixation. Due to growing concerns with static screw fixation, implants based on the flexible suture button design, such as the TightRope system, gained traction. Advantages with these designs include superior outcome scores, as well as lower rates of osteoarthritis and reoperation7,9,10. However, despite achieving improved joint mechanics, these systems have their drawbacks as well, such as infection or damage to the superficial medial neurovascular bundle9. The Fibulink Syndesmosis Repair System, a relatively new design that became clinically available in 2017, has showed promising results. It has been promoted as an implant that potentially provides both the fixation of a screw and flexibility of a suture to respect the dynamic nature of the ankle joint. Benefits of this design include eliminating damage to the medial neurovascular bundle and soft tissues, promoting physiologic motion of the ankle joint, and allowing improved tension control. In a case series with 14 patients that received the Fibulink implant, Desai found no complications with a mean follow-up of 9.5 months9. However, more long-term data is needed in order to draw any conclusions. The potential advantage of this system over suture button designs is that it incorporates the rigidity of screw fixation on top of the dynamic fixation of suture button implants. It also addresses the limitations of suture button designs, such as avoiding medial soft tissue disruption and lack of two-way tension control. The comparison between screw fixation and suture button designs has been thoroughly investigated in the literature. To our knowledge, there is no study that directly compares outcomes with the Fibulink implant to suture button implants. It is imperative to directly compare these methods so we can definitively assess their suitability and provide patients that sustain these injuries the best method of fixation in order to improve patient outcomes. The purpose of this study is to compare radiographic and clinical outcomes in patients who sustain an acute ankle fracture with an associated syndesmosis injury by comparing two surgical treatments currently in the practice of the study investigators. The study will compare suture button fixation versus Fibulink implant in patients with this injury. Inadequate syndesmosis fixation has been found to result in significant morbidity to patients, including persistent pain, instability, and post-traumatic arthritis. This emphasizes the need to assess the available methods of fixation in order to minimize negative long-term consequences. Currently, standard single screw fixation remains a common choice among orthopaedic surgeons. However, there is some evidence of superior outcomes with dynamic fixation, using designs such as the suture button or the Fibulink system, in terms of functional results, residual pain, and other measures. With an enhanced understanding of patient outcomes with these methods of fixation, we will better be able to determine more effective ways to manage these injures and offer guidance for optimal management and patient satisfaction.
Phase
N/ASpan
109 weeksSponsor
United States Naval Medical Center, San DiegoSan Diego, California
Recruiting
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
PRIMARY OBJECTIVES: I. To evaluate the failure free survival (FFS) of patients with very low-risk (VLR) rhabdomyosarcoma (RMS) (fusion negative [FN], stage 1, clinical group [CG] I, MYOD1 wildtype [WT], TP53 [WT]) when treated with 24 weeks of vincristine and dactinomycin (VA). II. To evaluate the FFS of patients with low-risk (LR) RMS (FN, stage 1 CG II, or stage 2 CG I/II or CG III [orbit only], MYOD1 WT, TP53 WT) when treated with 12 weeks of vincristine, dactinomycin and cyclophosphamide (VAC) followed by 12 weeks of VA. SECONDARY OBJECTIVES: I. To evaluate the overall survival (OS) of patients with VLR RMS treated with 24 weeks of VA. II. To evaluate the OS of patients with LR RMS treated with 12 weeks of VAC followed by 12 weeks of VA. III. To demonstrate the feasibility of central molecular risk stratification of patients with newly diagnosed RMS in the context of a prospective clinical trial. EXPLORATORY OBJECTIVES: I. To collect blood and tissue samples for banking at baseline, during treatment, at the end of therapy, and at the time of progression to bank for future research. II. To describe the methylation array profile of patients with fusion negative, low-risk rhabdomyosarcoma. III. To describe the outcomes of patients with VLR or LR RMS and MYOD1 or TP53 mutations treated with intensified therapy. OUTLINE: Patients are assigned to 1 of 2 regimens based on clinical features. Patients with positive mutation status are transitioned to a third regimen, Regimen M. REGIMEN VA: Patients with VLR RMS receive vincristine intravenously (IV) on day 1 of each cycle and days 8 and 15 of cycles 1, 3, 5, and 7 and dactinomycin IV over 1-5 minutes or over 10-15 minutes on day 1 of each cycle. Treatment repeats every 21 days for 8 cycles in the absence of disease progression or unacceptable toxicity. Patients with MYOD1 or TP53 mutated tumors transition to Regimen M at cycle 2 (if mutation status is determined to be positive at week 3) or cycle 3 (if mutation status is determined to be positive after week 3). REGIMEN VAC/VA: Patients with LR RMS receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 1-3. Patients also receive dactinomycin IV over 1-5 minutes or 10-15 minutes and cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 5-7 and dactinomycin IV over 1-5 minutes or over 10-15 minutes on day 1 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients with MYOD1 or TP53 mutated tumors transition to Regimen M at cycle 2 (if mutation status is determined to be positive at week 3) or cycle 3 (if mutation status is determined to be positive after week 3). Patients may also undergo radiation therapy at cycle 5. REGIMEN M: Patients receive vincristine IV on day 1 of each cycle and days 8 and 15 of cycles 2-4, 7-8, and 11-12 and dactinomycin IV over 1-5 minutes or 10-15 minutes on day 1 of cycles 2-5 and 8-14. Patients also receive cyclophosphamide IV over 60 minutes on day 1 of each cycle. Treatment repeats every 21 days for 12-13 cycles in the absence of disease progression or unacceptable toxicity. Patients may also undergo radiation therapy at cycle 5. Patients undergo computed tomography (CT) scan, magnetic resonance imaging (MRI), bone scan, positron emission tomography (PET) scan and tumor biopsy throughout the study.
Phase
3Span
413 weeksSponsor
Children's Oncology GroupSan Diego, California
Recruiting